You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金下調藥明生物(02269.HK)目標價至57元 評級「跑贏行業」
阿思達克 12-05 14:34
中金發表報告指,藥明生物(02269.HK昨日(4日)召開業務進展更新電話會,下調今年至後年業績指引。 公司指引今年收入增長10%(其中新冠佔比少於3%,扣除新冠按年增長36%),經調整淨利潤個位數下滑(此前指引今年收入增長30%,經調整淨利潤增長26至27%;指引明年收入及經調整淨利潤雙位數增長(新冠收入佔比少於1%),後年收入和經調整淨利潤30%增長(此前指引為今年至後年收入年複合增長率30%,經調整淨利潤CAGR為26至27%)。 報告指,由於藥明生物合同生產服務(CDO)/合同生產服務(CMO)業務不及預期、行業增速下降等,下調今明兩年經調整每股盈利預測各25%和28%至1.1和1.3元,維持「跑贏行業」評級,下調目標價30.5%至57元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account